CA2907909A1 - Cellular markers for diagnosis of alzheimer's disease and for alzheimer's disease progression - Google Patents
Cellular markers for diagnosis of alzheimer's disease and for alzheimer's disease progressionInfo
- Publication number
- CA2907909A1 CA2907909A1 CA2907909A CA2907909A CA2907909A1 CA 2907909 A1 CA2907909 A1 CA 2907909A1 CA 2907909 A CA2907909 A CA 2907909A CA 2907909 A CA2907909 A CA 2907909A CA 2907909 A1 CA2907909 A1 CA 2907909A1
- Authority
- CA
- Canada
- Prior art keywords
- cd11b
- cells
- level
- lin
- cell type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261615465P | 2012-03-26 | 2012-03-26 | |
| US61/615,465 | 2012-03-26 | ||
| PCT/IL2013/050277 WO2013144957A1 (en) | 2012-03-26 | 2013-03-21 | Cellular markers for diagnosis of alzheimer's disease and for alzheimer's disease progression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2907909A1 true CA2907909A1 (en) | 2013-10-03 |
Family
ID=49258360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2907909A Abandoned CA2907909A1 (en) | 2012-03-26 | 2013-03-21 | Cellular markers for diagnosis of alzheimer's disease and for alzheimer's disease progression |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20150057176A1 (https=) |
| EP (1) | EP2831584B1 (https=) |
| JP (1) | JP6276252B2 (https=) |
| KR (1) | KR20140145173A (https=) |
| CN (1) | CN104471394B (https=) |
| AU (1) | AU2013239070A1 (https=) |
| CA (1) | CA2907909A1 (https=) |
| ES (1) | ES2819174T3 (https=) |
| IL (1) | IL234779A (https=) |
| WO (1) | WO2013144957A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6312302B2 (ja) * | 2014-01-06 | 2018-04-18 | 公益財団法人ヒューマンサイエンス振興財団 | 脳梗塞の診断マーカー |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| JP6499342B2 (ja) * | 2018-03-19 | 2019-04-10 | 隆樹 日和佐 | 脳梗塞の診断マーカー |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| US20220170908A1 (en) * | 2019-03-26 | 2022-06-02 | Anton Wyss-Coray | Compositions and methods for characterizing and treating alzheimers disease |
| WO2021072650A1 (zh) * | 2019-10-15 | 2021-04-22 | 湖南乾康科技有限公司 | 中间型单核细胞在制备诊断和预测ad药物中的应用 |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| CN112562867A (zh) * | 2021-02-22 | 2021-03-26 | 天津迈德新医药科技有限公司 | 一种预测极早期hiv感染风险的装置、存储介质和电子装置 |
| CN118103710A (zh) | 2021-08-09 | 2024-05-28 | 安元有限公司 | 用于检测临床前阿兹海默氏病的组合物、试剂盒和方法 |
| EP4426295A1 (en) * | 2021-11-02 | 2024-09-11 | Tranquis Therapeutics, Inc. | Selection and treatment of subjects having a circulating myeloid cell inflammatory phenotype |
| KR102745500B1 (ko) * | 2022-09-02 | 2024-12-23 | 한양대학교 에리카산학협력단 | 혈액 대사체를 이용한 치매 스크리닝 장치 및 방법 |
| CN116270741B (zh) * | 2023-02-28 | 2025-10-24 | 东莞市东南部中心医院 | 骨髓源性抑制细胞在制备治疗阿兹海默症药物或试剂中的应用 |
| CN117122612B (zh) * | 2023-07-07 | 2024-08-27 | 河络新图生物科技(上海)有限公司 | 外周血单个核细胞在制备治疗/预防阿尔茨海默病的药物中的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4328050B2 (ja) * | 2000-01-20 | 2009-09-09 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用 |
| US20020137108A1 (en) * | 2000-11-08 | 2002-09-26 | Michael Mullan | CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker in alzheimer's disease |
| US7351686B2 (en) * | 2001-12-06 | 2008-04-01 | Yeda Research And Development Co. Ltd. | Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides |
| CN100591761C (zh) * | 2004-08-19 | 2010-02-24 | 加的夫大学学院咨询有限公司 | 呈递抗原的人γδT细胞的制备和在免疫治疗中的用途 |
| JP5771525B2 (ja) * | 2008-09-18 | 2015-09-02 | セダーズ−シナイ メディカル センター | アルツハイマー病を検出するための光学的方法 |
| WO2011111043A1 (en) | 2010-03-10 | 2011-09-15 | Yeda Research And Development Co. Ltd | Cellular blood markers for early diagnosis of als and for als progression |
-
2013
- 2013-03-21 WO PCT/IL2013/050277 patent/WO2013144957A1/en not_active Ceased
- 2013-03-21 US US14/388,369 patent/US20150057176A1/en not_active Abandoned
- 2013-03-21 EP EP13767635.9A patent/EP2831584B1/en active Active
- 2013-03-21 CN CN201380027520.5A patent/CN104471394B/zh active Active
- 2013-03-21 JP JP2015502555A patent/JP6276252B2/ja active Active
- 2013-03-21 AU AU2013239070A patent/AU2013239070A1/en not_active Abandoned
- 2013-03-21 ES ES13767635T patent/ES2819174T3/es active Active
- 2013-03-21 CA CA2907909A patent/CA2907909A1/en not_active Abandoned
- 2013-03-21 KR KR1020147029916A patent/KR20140145173A/ko not_active Withdrawn
-
2014
- 2014-09-22 IL IL234779A patent/IL234779A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JP6276252B2 (ja) | 2018-02-07 |
| EP2831584A4 (en) | 2015-10-07 |
| CN104471394A (zh) | 2015-03-25 |
| WO2013144957A1 (en) | 2013-10-03 |
| EP2831584A1 (en) | 2015-02-04 |
| JP2015511721A (ja) | 2015-04-20 |
| AU2013239070A1 (en) | 2014-11-13 |
| US20150057176A1 (en) | 2015-02-26 |
| IL234779A (en) | 2017-12-31 |
| CN104471394B (zh) | 2017-04-05 |
| ES2819174T3 (es) | 2021-04-15 |
| EP2831584B1 (en) | 2020-06-17 |
| KR20140145173A (ko) | 2014-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2831584B1 (en) | Cellular markers for diagnosis of alzheimer's disease and for alzheimer's disease progression | |
| Larbi et al. | Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer's disease | |
| Richartz et al. | Decline of immune responsiveness: a pathogenetic factor in Alzheimer’s disease? | |
| Milo et al. | Revised diagnostic criteria of multiple sclerosis | |
| Saresella et al. | Increased activity of Th-17 and Th-9 lymphocytes and a skewing of the post-thymic differentiation pathway are seen in Alzheimer’s disease | |
| Frisullo et al. | IL17 and IFNγ production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis | |
| Xu et al. | High prevalence of mild cognitive impairment in the elderly: a community-based study in four cities of the Hebei Province, China | |
| US20150209404A1 (en) | Cellular blood markers for early diagnosis of als and for als progression | |
| Fahmi et al. | Neutrophil-lymphocyte ratio as a marker for disability and activity in multiple sclerosis | |
| Hatemi et al. | One year in review 2017: Behçet’s syndrome | |
| Martins et al. | Disease-specific expression of the serotonin-receptor 5-HT2C in natural killer cells in Alzheimer's dementia | |
| Chen et al. | Type 1 diabetes patients have significantly lower frequency of plasmacytoid dendritic cells in the peripheral blood | |
| Wu et al. | A change of PD-1/PD-L1 expression on peripheral T cell subsets correlates with the different stages of Alzheimer's disease | |
| Roda et al. | Ataxia with oculomotor apraxia type 2 fibroblasts exhibit increased susceptibility to oxidative DNA damage | |
| Pan et al. | MD-1 deficiency attenuates dextran sodium sulfate (DSS)-induced colitis through modulating the function of colonic lamina propria dendritic cells | |
| Frisullo et al. | The persistency of high levels of pSTAT3 expression in circulating CD4+ T cells from CIS patients favors the early conversion to clinically defined multiple sclerosis | |
| JP6115979B2 (ja) | Ｓｍｎタンパク質の発現を検出する方法 | |
| Etemadifar et al. | Anti-aquaporin-4 IgG in patients presenting with unilateral optic neuritis: a cohort study | |
| Bădulescu et al. | Immune thrombocytopenic purpura: Correlations between thrombocytopenia severity and its clinical symptoms | |
| JP4455753B2 (ja) | 精神分裂病の皮膚テスト | |
| Al-Khateeb | Senescence and immune response after traumatic brain injury in juvenile and adult mice | |
| Richartz-Salzburger et al. | Decline of Immune Responsiveness: A Pathogenetic Factor in Alzheimer’s Disease? | |
| Yu et al. | Predictive value of peripheral blood lymphocytes for glaucoma susceptibility: a clinical observational study | |
| Jiao et al. | Confocal Corneal Microscopy in the Evaluation of Immune-related Motor Neuron Disease Syndrome | |
| JP2025099732A (ja) | 慢性移植片対宿主病の発症を予測するためのバイオマーカー、および判定方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20190321 |